TAK-280, SILTUXIMAB, TOCILIZUMAB, TOCILIZUMAB, SILTUXIMAB, TOCILIZUMAB
TAK-280-1501
Phase 2 small_molecule active
Quick answer
TAK-280, SILTUXIMAB, TOCILIZUMAB, TOCILIZUMAB, SILTUXIMAB, TOCILIZUMAB for Unresectable Locally Advanced or Metastatic Cancer is a Phase 2 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Unresectable Locally Advanced or Metastatic Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active